Visit our new Fragment Library Web-site at

Zenobia Therapeutics scientists are pioneers in the field of fragment-based lead discovery and applying it to CNS disease.  Our technology allows us to rapidly identify potent and selective lead compounds with properties consistent with CNS penetration.  Our current focus is on targets misregulated in neurodegenerative diseases.  We have demonstrated proof of concept for our most advanced LRRK2 Parkinson's disease program.

Zenobia News

Website Builder